<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02857361</url>
  </required_header>
  <id_info>
    <org_study_id>KET011</org_study_id>
    <nct_id>NCT02857361</nct_id>
  </id_info>
  <brief_title>Crossover Study to Evaluate the PK Effects of Two Different Wafer Administration Protocols.</brief_title>
  <official_title>An Open Label, Two-way Crossover Study to Evaluate the PK Effects of Two Different Wafer Administration Protocols in Healthy Volunteers Under Fasted Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iX Biopharma Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iX Biopharma Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will look at whether it is preferable to administer two wafers simultaneously or&#xD;
      separately.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability</measure>
    <time_frame>10 hours</time_frame>
    <description>Plasma concentrations collected for 10 hours after simultaneous wafer administration and sequential wafer administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of treatment related adverse events</measure>
    <time_frame>From time of initial dose until 3 days after final dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Acceptance</measure>
    <time_frame>20 minutes</time_frame>
    <description>Participant will rate their experience by completing a questionnaire 20 minutes after each dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Administrator Acceptance</measure>
    <time_frame>20 minutes</time_frame>
    <description>The person administering drug will rate their experience by completing a questionnaire 20 minutes after each dose.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Treatment A: Simultaneous Administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual ketamine 50mg (2 x 25mg wafers) administered simultaneously at T=0 minute.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: Sequential Administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual ketamine 50mg (2 x 25mg wafers) administered sequentially, one 25 mg wafer at T=0 minute and one 25 mg wafer at T=3 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual ketamine wafers</intervention_name>
    <description>Two sublingual ketamine 25 mg wafers</description>
    <arm_group_label>Treatment A: Simultaneous Administration</arm_group_label>
    <arm_group_label>Treatment B: Sequential Administration</arm_group_label>
    <other_name>Wafermine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females aged 18-65 years.&#xD;
&#xD;
          -  Good general health without clinically significant renal, hepatic, cardiac or&#xD;
             respiratory disease, as determined by the Principal Investigator.&#xD;
&#xD;
          -  Willing and able to give informed consent and agree to complete all study procedures.&#xD;
&#xD;
          -  Have suitable venous access for blood sampling.&#xD;
&#xD;
          -  Female participants are eligible only if all the following apply:&#xD;
&#xD;
               1. Not pregnant (women of child bearing potential must have a negative serum&#xD;
                  pregnancy test at screening and negative urine pregnancy test at check-in for&#xD;
                  each inpatient period);&#xD;
&#xD;
               2. Not lactating;&#xD;
&#xD;
               3. Not planning to become pregnant during the study;&#xD;
&#xD;
               4. Be surgically sterile (irreversible surgical sterilisation by hysterectomy,&#xD;
                  bilateral oophorectomy, or bilateral salpingectomy), or have undergone bilateral&#xD;
                  tubal ligation; or be at least two years post-menopausal; or is practicing&#xD;
                  double-barrier contraception or is using an insertable, injectable, transdermal,&#xD;
                  or combination oral contraceptive for greater than 2 months prior to screening&#xD;
                  visits and commits to the use of an acceptable form of highly effective birth&#xD;
                  control for the duration of the study and for 30 days after the last dose study&#xD;
                  drug administration.&#xD;
&#xD;
          -  BMI within the range of 19-30 kg/m2 (inclusive).&#xD;
&#xD;
          -  Deemed able to read and understand English in order to communicate with research staff&#xD;
             and complete protocol required questionnaires and forms.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a laboratory value at the Screening Visit that is outside the normal range, unless&#xD;
             it is judged by the Investigator as not clinically significant after appropriate&#xD;
             evaluation. One repeat of initial laboratory testing is allowed.&#xD;
&#xD;
          -  AST, ALT and ALP tests in excess of 1.5 times the upper limit of normal.&#xD;
&#xD;
          -  Any gastrointestinal condition that could affect drug absorption.&#xD;
&#xD;
          -  History of any clinically significant condition involving the bladder or urinary&#xD;
             tract, including frequent urinary tract infections (e.g. &gt; 2 per year), or current&#xD;
             symptoms of bladder irritation such as frequent or urgent need to urinate or burning&#xD;
             with urination.&#xD;
&#xD;
          -  History (within the last six months) of or current clinically significant psychiatric&#xD;
             disorder including anxiety, psychosis or depression.&#xD;
&#xD;
          -  Current inflammatory or ulcerative disease of the oral cavity that could impair the&#xD;
             absorption of sublingual medication.&#xD;
&#xD;
          -  History of severe allergic or anaphylactic drug-related reactions.&#xD;
&#xD;
          -  History of hypersensitivity to ketamine or any of the excipients of Wafermineâ„¢.&#xD;
&#xD;
          -  Intake of any prescribed or Over-The-Counter (OTC)/non-prescribed drugs, vitamins,&#xD;
             supplements or herbal medicines, within 2 weeks of administration of investigational&#xD;
             product (or longer if the medication has a half-life long enough to potentially expose&#xD;
             the healthy participant to any significant systemic exposure). Exception: Hormone&#xD;
             replacement therapy and oral contraceptives in female participants is allowed.&#xD;
&#xD;
          -  Use of drugs with enzyme-inducing properties, such as rifampicin and St John's Wort,&#xD;
             within 3 weeks or 5 half-lives, whichever is greater, prior to treatment period 1 and&#xD;
             throughout the study, or any drug known to be a strong inhibitor of CYP3A4 within 5&#xD;
             half-lives of treatment period 1 and throughout the study.&#xD;
&#xD;
          -  Participation in another clinical trial of an investigational agent within 30 days of&#xD;
             screening.&#xD;
&#xD;
          -  Positive serology for hepatitis C virus (HCV), hepatitis B or human immunodeficiency&#xD;
             virus (HIV).&#xD;
&#xD;
          -  Clinically significant, as determined by the Investigator, abnormal ECG (12-lead) or&#xD;
             vital signs at the screening visit or pre-dose on any treatment day.&#xD;
&#xD;
          -  Known or suspected drug (including analgesic drugs or tranquilizers) or alcohol abuse&#xD;
             or dependence, as defined by DSM-IV, and not in full remission, as judged by the&#xD;
             Investigator, or history of alcohol abuse or excessive intake of alcohol, defined as&#xD;
             regular weekly intake of &gt;15 units for men and &gt;10 units for women. (1 unit = 25 mL&#xD;
             spirits, 125 mL wine, 250 mL beer or lager.)&#xD;
&#xD;
          -  Positive results on the urine drug screen or breath alcohol test at screening and/or&#xD;
             pre-dose. A positive result on the urinary drug screen at screening is allowed at the&#xD;
             discretion of the Investigator provided the result can be reliably explained by recent&#xD;
             medication and/or dietary history.&#xD;
&#xD;
          -  Significant history of illicit drug use (as determined by the Investigator).&#xD;
&#xD;
          -  Any alcohol use within 24 hours prior to each inpatient treatment period.&#xD;
&#xD;
          -  Unwillingness or inability to comply with the requirements of this protocol, including&#xD;
             the presence of any condition (physical, mental, or social) that is likely to affect&#xD;
             the participant returning for subsequent visits on schedule.&#xD;
&#xD;
          -  Blood donation (1 unit or more) within 1 month prior to the screening visit and until&#xD;
             the end of study participation.&#xD;
&#xD;
          -  Current or previous tobacco user (within 12 months prior to screening).&#xD;
&#xD;
          -  Participants who routinely consume more than four standard caffeinated beverages per&#xD;
             24-hour period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam Salman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>iX Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 2, 2016</study_first_submitted>
  <study_first_submitted_qc>August 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

